What You Should Know
- Eli Lilly and Company has entered a strategic collaboration with Chai Discovery to deploy frontier AI for the design of novel biologic therapeutics.
- The partnership includes the development of an exclusive, purpose-built AI model trained on Lilly’s proprietary data, leveraging Chai's Chai-2 platform to compress discovery timelines from months to weeks.
The "Zero-Shot" Revolution: Slashing Discovery Timelines
In the world of biologics, antibody design has
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Amazon Pharmacy Disrupts Weight Loss Market with Oral Wegovy: $149 Cash-Pay Option and Same-Day Delivery
What You Should Know
- Amazon Pharmacy has officially added Novo Nordisk’s Wegovy® pill—the first and only FDA-approved oral GLP-1 for weight management—to its nationwide delivery platform.
- To lower barriers to care, Amazon is offering a transparent cash-pay option starting at $149 per month for those without insurance, while eligible commercially insured customers may pay as little as $25.
The Oral Shift: Removing the Needle Barrier
The "Wegovy pill" represents a massive
Read More
Smarter Media Planning: How Pharma Marketers are Solving the 2026 FDA Compliance Gap
Pharma advertising is entering a period of accelerated change. As the Food and Drug Administration increases oversight of direct‑to‑consumer promotions, marketers are rethinking how they reach patients and consumers. New guidance aimed at improving risk communication and ensuring message accuracy is prompting brands to diversify their media strategies and invest in channels that balance reach, trust, and regulatory responsibility.
Marketers Are Reassessing the Full Advertising Mix
Spending
Read More
Topos Bio Emerges from Stealth to Tackle Disordered Proteins with $10.5M and Frontier AI
What You Should Know
- Topos Bio has emerged from stealth with $10.5M in seed funding to solve one of the most persistent challenges in medicine: targeting intrinsically disordered proteins (IDPs). The seed funding was led by Boldstart, Threshold, and Neo, with participation from notable angel investors including Dara Khosrowshahi (CEO of Uber) and Naveen Rao (CEO of Unconventional AI).
- While traditional models like AlphaFold focus on static structures, Topos Bio’s foundation model,
Read More
Verana Health Acquires COTA to Build Multi-Specialty RWD Powerhouse
What You Should Know:
- Verana Health®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD), has announced the merger with COTA Healthcare®.
- The merger expands the company’s therapeutic offerings in data and software solutions for real-world insights that accelerate clinical research, expedite treatment options, and improve patient care. Terms of the transaction were not disclosed.
Building a Multi-Specialty Engine for
Read More
From Genes to Hackers: The Hidden Cybersecurity Risks in Life Sciences
Getting a new credit card number is relatively easy, but you can't get a new genome.
In October 2023, 23andMe experienced a data breach resulting from a credential stuffing attack. In this cyberattack, hackers exploit reused usernames and passwords obtained from previous data leaks to gain unauthorized access to user accounts. Initially, approximately 14,000 accounts were compromised. It exposed the sensitive personal and genetic data of about 5.5 million users and an additional 1.4
Read More
The $149 Disruptor: GoodRx WeightWatchers, LifeMD Aggressively Scale Access to FDA-Approved Wegovy Pill
What You Should Know:
- The healthcare landscape is witnessing a seismic shift in obesity care as GoodRx, WeightWatchers LifeMD launch the newly FDA-approved Wegovy pill (oral semaglutide) with a transparent cash-pay price of $149 per month.
- By combining 16.6% mean weight loss efficacy with a vast retail and telehealth infrastructure, this rollout effectively removes the twin barriers of injection hesitancy and opaque "middleman" pricing.
Breaking the Injection Barrier: The
Read More
AI in Pharmacovigilance: Balancing Innovation with Regulatory Trust in 2026
Pharmacovigilance (PV) is experiencing a renaissance. Artificial Intelligence (AI) is no longer a futuristic concept in PV; it’s here, reshaping how we manage safety data, detect signals and maintain compliance. From automating case intake to accelerating literature screening and supporting aggregate reporting, AI promises efficiency and scalability at a time when data volumes and regulatory expectations are soaring. Yet, for all its potential, AI introduces a new challenge:
Read More
Unlocking Real-World Evidence: 5 Questions to Ask Before Trusting AI-Curated RWD
In today’s pharmaceutical industry, real-world evidence (RWE) offers significant potential across all phases of the product life cycle, from trial design to product launch, from pricing and competitive reviews to evaluating the effects of switching medications.
As RWE becomes a key tool for life sciences organizations to shape clinical trial strategies, advance treatment development, and meet regulatory requirements, the quality of the underlying data and trust in how it was generated is
Read More
The “One Shot” Cure? How Vyriad’s $85M Raise Could Replace Complex CAR-T Labs with a Single Injection
What You Should Know:
- Vyriad, Inc. has secured the final $25M of its Series B financing, bringing the total round to $85M led by Mr. Harry Stine of Stine Seed Farms, Inc.
- The funding will power the first-in-human trials of VV169, an in vivo CAR-T therapy for multiple myeloma that modifies immune cells directly inside the patient’s body. This approach eliminates the complex, expensive lab manufacturing required by current CAR-T treatments, potentially offering a scalable,
Read More
